Cempra, Inc. (NASDAQ:CEMP)‘s stock had its “hold” rating reiterated by research analysts at Stifel Nicolaus in a research note issued on Thursday. They presently have a $4.00 price target on the biotechnology company’s stock. Stifel Nicolaus’ price objective would suggest a potential upside of 9.59% from the company’s current price.
Several other analysts also recently commented on the stock. Vetr raised shares of Cempra from a “buy” rating to a “strong-buy” rating and set a $4.86 price objective on the stock in a report on Monday, May 1st. Zacks Investment Research raised shares of Cempra from a “hold” rating to a “buy” rating and set a $4.50 price objective on the stock in a report on Tuesday, May 2nd. Jefferies Group LLC reaffirmed a “hold” rating and issued a $3.00 price objective on shares of Cempra in a report on Thursday, May 25th. Finally, ValuEngine downgraded shares of Cempra from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Four investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $11.34.
Cempra (NASDAQ:CEMP) opened at 3.65 on Thursday. The firm has a 50-day moving average of $4.24 and a 200 day moving average of $3.84. Cempra has a 52-week low of $2.55 and a 52-week high of $26.95. The company’s market capitalization is $191.64 million.
Cempra (NASDAQ:CEMP) last released its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.09. The business had revenue of $0.86 million for the quarter, compared to the consensus estimate of $3.58 million. Cempra had a negative net margin of 551.45% and a negative return on equity of 56.60%. The business’s revenue for the quarter was down 74.9% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.51) EPS. Equities analysts predict that Cempra will post ($1.06) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This story was first posted by Ticker Report and is the property of of Ticker Report. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at https://www.tickerreport.com/banking-finance/2796679/cempra-inc-cemp-receives-hold-rating-from-stifel-nicolaus.html.
Several institutional investors have recently bought and sold shares of CEMP. State Street Corp boosted its position in Cempra by 85.8% in the fourth quarter. State Street Corp now owns 2,133,275 shares of the biotechnology company’s stock valued at $5,973,000 after buying an additional 985,427 shares in the last quarter. Pennsylvania Trust Co purchased a new position in Cempra during the second quarter valued at about $7,784,000. Renaissance Technologies LLC boosted its position in Cempra by 175.0% in the first quarter. Renaissance Technologies LLC now owns 1,680,500 shares of the biotechnology company’s stock valued at $6,302,000 after buying an additional 1,069,300 shares in the last quarter. Bogle Investment Management L P DE boosted its position in Cempra by 607.0% in the first quarter. Bogle Investment Management L P DE now owns 709,518 shares of the biotechnology company’s stock valued at $2,660,000 after buying an additional 609,168 shares in the last quarter. Finally, South Dakota Investment Council boosted its position in Cempra by 19.6% in the first quarter. South Dakota Investment Council now owns 706,207 shares of the biotechnology company’s stock valued at $2,648,000 after buying an additional 115,707 shares in the last quarter. Hedge funds and other institutional investors own 52.28% of the company’s stock.
Cempra, Inc is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP).
Receive News & Ratings for Cempra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cempra Inc. and related companies with MarketBeat.com's FREE daily email newsletter.